Sangamo Therapeutics Inc.

BioCentury’s Deals Report: Wuxi Biologics, Hutchmed in asset sales and more

Penn.-based commercial payer using accelerated approval to justify coverage denials of non-oncology products for 18 months

FDA will accept Phase I/II data on Fabry gene therapy, obviating need for Phase III trial

Plus: Denmark-based Pharmacosmos buys G1, obtaining myelosuppression drug

Companies and academics showcase two approaches to make AAV capsids with enhanced brain targeting and suppressed liver targeting

Biotech identifies ALPL as a cross-species cell surface receptor mediating BBB crossing of AAV capsid family

As the new modality advances, the promise of durability is bearing out in preclinical models

Plus: new COO for radiopharma 

BioCentury’s roundup of translational innovations

Plus: leadership changes at Valo and more from Mirum, Arvinas, Vaxcyte, Lantern and Inhibikase